Wantai Bio
On January 23, Wantai Biotech issued a performance reduction announcement, saying that it is expected that the net profit attributable to the owners of the parent company in 2023 will be 1.2 billion yuan to 13500 million yuan, a decrease of 74 compared with the same period last year66% to 7149%；It is estimated that the non-net profit attributable to the parent in the same period will be 10500 million yuan to 1.2 billion yuan, a year-on-year decrease of 7674% to 7342%。Wantai Biotech said that the reason for the decline in performance was the decline in revenue from bivalent cervical cancer vaccine and new crown-related businesses. Ruiang Gene
1. According to the preliminary calculation of the financial department, Ruiang Gene expects to achieve a net profit attributable to the owners of the parent company of 649 in 2023890,000 yuan to 974$840,000, a decrease of $3,072 compared to the same period last year (statutory disclosure data).$520,000 to $3,397470,000 yuan, a year-on-year decrease of 7591% to 8394%。2. The company expects to achieve a net profit attributable to the owners of the parent company after deducting non-recurring gains and losses of 335 in 2023390,000 yuan to 5030.9 million yuan, a decrease of 2,856 compared with the same period last year (statutory disclosure data).$820,000 to $3,024520,000 yuan, a year-on-year decrease of 8503% to 9002%。
Kang for the century
According to the 2023 annual performance forecast released by Kangwei Century, according to the preliminary calculation of the financial department, the company expects that the net profit attributable to the owners of the parent company in 2023 will be a loss compared with the same period last year, and the net profit attributable to the owners of the parent company will be -75 million yuan to -90 million yuan, a decrease of 147 compared with the same period last year09% to 15651%。Estimated net profit attributable to owners of the parent company after deducting non-recurring gains and losses -10,8000000000 to -12,400000,000 yuan, a decrease of 172 compared with the same period last year54% to 18328%。
MGI
On January 30, MGI released its 2023 annual performance forecast. According to the company's preliminary estimates, in 2023, it is expected that the sales revenue of the gene sequencer segment will increase by about 30% year-on-year; Net profit attributable to the parent company - 6$8.7 billion to -5$7.8 billion; Net profit after deducting non-profit -7$6.8 billion to -64.6 billion yuan. According to the announcement, the reasons for the pre-loss are mainly three aspects: First, 3. The payment received from Illumina in the same period last year$2.5 billion in net compensation costs resulted in a large prior-period base; second, the decline in gross profit contribution due to the shrinking demand for laboratory automation products; Third, in order to maintain its own advanced technology and global sales layout, the company's R&D and sales investment has increased.
Nearshore proteins1. According to the preliminary calculation of the financial department, it is expected to achieve operating income of 1 in 20234.5 billion to 15.4 billion yuan, a decrease of 1 over the same period last year19.5 billion to 110.5 billion yuan, a year-on-year decrease of 4519% to 4179%。2. The company expects that the net profit attributable to shareholders of listed companies in 2023 will be 12.5 million yuan to 14 million yuan, a decrease of 77.92 million yuan to 76.42 million yuan over the same period of the previous year, a year-on-year decrease of 8618% to 8452%。3. The company expects that the net profit attributable to shareholders of listed companies in 2023 after deducting non-recurring gains and losses will be -7.5 million yuan to -6 million yuan, a decrease of 85.1 million yuan to 83.6 million yuan over the same period last year, a year-on-year decrease of 10967% to 10773%。Seili MedicalOn January 31, Saili Medical released an annual performance forecast, and the company expects to reduce losses from January to December 2023, and the net profit attributable to shareholders of listed companies will be -15 billion - 11.5 billion, net profit increased by 2 percent year-on-year86% to 2553%NovizanOn January 30, Nuovezan released a 2023 performance forecast, saying that the company expects to achieve a net profit attributable to the parent company of -0 in 20237.5 billion to -06 billion yuan, to achieve a net profit of -20.5 billion to -1$8.5 billion; Achieved operating income of 126 billion to 130 billion yuan, a year-on-year decrease of 6358% to 6470%。Nuovezan said that multiple factors have led to a sharp decline in the demand for related testing raw materials and end products in the downstream market, and the revenue of this part of the business will decline sharply in 2023. In 2023, the company will focus on R&D investment, project management, and focus on reducing costs and increasing efficiency, and the level of operating costs will show a trend of improvement quarter by quarter, but the overall cost decline will still lag behind. The company made impairment provisions for some inventories and bad debts, and at the same time, the company's profit in 2023 was affected due to the implementation of the restrictive ** incentive plan to amortize share-based payment expenses. YahuilongOn January 24, Yahuilong released an annual performance forecast, and the company expects a significant decline in performance from January to December 2023, and the net profit attributable to shareholders of listed companies will be 34 billion - 39 billion, net profit decreased by 66 year-on-year42% to 6148%。The company made the above ** based on the following reasons: In 2023, the company's new crown business operating income and gross profit margin decreased significantly compared with the same period last year, resulting in a year-on-year decline in the company's net profit attributable to owners of the parent company in 2023. In 2023, as terminal diagnosis and treatment activities gradually return to normal, the product strength and brand of the company's self-produced chemiluminescence and other self-produced products will be widely recognized, the cumulative installed capacity of chemiluminescence instruments will gradually increase, and the revenue growth rate of the company's self-produced chemiluminescence and other self-produced products will meet the company's expectations. Golden Mile MedicineOn January 31, Jinyu Medical released an annual performance forecast, and the company expects a significant decline in performance from January to December 2023, with a net profit attributable to shareholders of listed companies of 60 billion - 73 billion, net profit decreased by 78 percent year-on-year20% to 7348%。The company made the above decision based on the following reasons: During the reporting period, the company's net profit attributable to shareholders of listed companies decreased by 63 year-on-year due to the decrease in demand for testing related to public health events67%-67.67%, net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses decreased by 74 percent year-on-year68%-76.89%。At the same time, due to the slower than expected growth rate of demand for routine testing and the high investment in fixed costs, the scale effect declined, resulting in a year-on-year decrease in net profit attributable to shareholders of listed companies of 981%-10.53%, net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses decreased by 9 percent year-on-year61%-10.35%。Berry GeneOn January 31, Berry Gene released its annual performance forecast, and the company expects to increase its losses from January to December 2023, and the net profit attributable to shareholders of listed companies will be -40 billion, net profit decreased by 57 year-on-year00% and expected basic earnings per share of -11300 yuan. During the reporting period, the company deeply cultivated the gene sequencing industry, focused on its main business, continuously promoted technological innovation and the landing of new products, and accelerated the layout of overseas markets. However, due to the impact of the main products entering the mature period, new products are still in the climbing stage, market competition is intensifying, and the first year is declining, the annual operating income decreased compared with the same period last year.
BGIOn January 30, BGI disclosed its 2023 annual performance forecast, and the company expects to achieve operating income of 4.2 billion yuan to 4.5 billion yuan and net profit of 80 million yuan to 1100 million yuan. As for the reasons for the change in performance, the announcement said that due to the impact of the industry cycle, the company's related testing business revenue has decreased significantly compared with the same period in 2022, and the company will continue to take the initiative to strategically adjust the product structure and chain strategy of its main business to promote the steady development of its main business. Among them, the business revenue of reproductive health and multi-omics increased slightly year-on-year, and the revenue of tumor prevention and control achieved significant year-on-year growth. Daan GeneOn January 31, Daan Gene released an annual performance forecast, and the company expects a significant decline in performance from January to December 2023, and the net profit attributable to shareholders of listed companies will be 10 billion - 13 billion, net profit decreased by 98 percent year-on-year15% to 9760%。The company made the above ** based on the following reasons: The main reasons for the year-on-year decline in the company's net profit attributable to shareholders of listed companies in 2023 are: during the reporting period, market demand decreased, the company's operating income decreased, and the net profit attributable to shareholders of listed companies decreased in the same direction. Yangpu MedicalOn January 30, Yangpu Medical released an annual performance forecast, and the company expects to reduce losses from January to December 2023, with a net profit attributable to shareholders of listed companies of -650000000--4500000,000, net profit increased by 67 percent year-on-year22% to 7731% and an estimated operating income of 64.1 billion yuan. The company made the above ** based on the following reasons: 1. During the reporting period, the company expects an operating income of about 64.1 billion yuan, 71.1 billion yuan, down 07 billion yuan, a decrease of 985%。Among them, the vacuum blood collection management system is expected to achieve revenue of 38.1 billion yuan, basically the same as the same period last year; The market demand for microbial transport systems has decreased significantly, and the revenue is expected to be approximately 372730,000 yuan, a decrease of 4,533 over the same period of the previous year670,000 yuan, a decrease of 9240%；Instruments and equipment are expected to achieve revenue of 2,484690,000 yuan, a decrease of 2,813 over the same period of the previous year380,000 yuan, a decrease of 5310%。Jiu'an MedicalOn January 30, Jiu'an Medical released its 2023 annual performance forecast. During the reporting period, it is expected to achieve a net profit attributable to the parent company of 1.1 billion yuan to 1.3 billion yuan, a decrease of 91 over the same period last year89%-93.14%；It is expected to achieve a net profit of 900 million yuan to 1.1 billion yuan, a decrease of 93 over the same period last year28%-94.50%。Jiu'an Medical said that in the same period last year, iHealth's in vitro diagnostic testing products sold well in the U.S. market, and the sales revenue of the products increased significantly. The performance of the reporting period decreased compared with the same period last year, mainly due to the decline in demand for related products in the U.S. market after normalization. Anxu BiotechOn January 31, Anxu Biotech released an annual performance forecast, and the company expects a significant decline in performance from January to December 2023, with a net profit attributable to shareholders of listed companies of 12.7 billion - 15.3 billion, net profit decreased by 95 percent year-on-year82% to 9498%。The company made the above ** based on the following reasons: 2023 is the impact of the end of global respiratory infectious diseases, the market demand for the company's related testing products has decreased significantly, the sales revenue has decreased significantly, and the company's net profit has decreased significantly. Biotest BiotechOn January 31, Biotest Biotech released its annual performance forecast, and the company expects a significant decline in performance from January to December 2023, with a net profit attributable to shareholders of listed companies of 10.6 billion - 11.6 billion, net profit decreased by 86 percent year-on-year30% to 8501%。The company made the above ** based on the following reasons: During the reporting period, the company's net profit decreased significantly year-on-year, mainly due to the sharp year-on-year decrease in sales revenue of new crown detection reagent products after the normalization of the new crown epidemic.
Aotai Biotech1. According to the preliminary calculation of the financial department, Aotai Biotech expects to achieve an annual operating income of 747 million yuan to 757 million yuan in 2023, a decrease of 2631.57 million yuan to 2641.57 million yuan compared with the same period last year (statutory disclosure data), a year-on-year decrease of 7766% to the annual expected net profit attributable to owners of the parent company of 165 million yuan to 175 million yuan, compared with the same period last year (statutory disclosure data), will be 1009.48 million yuan to 1019.48 million yuan, a year-on-year decrease of 8523% to the annual estimated net profit attributable to owners of the parent company after deducting non-recurring gains and losses of 115 million yuan to 125 million yuan, compared with the same period last year (statutory disclosure data), will be 1035.5 million yuan to 1045.5 million yuan, a year-on-year decrease of 8923% to 9009%。Zhijiang CreaturesOn January 31, Zhijiang Biotech released an annual performance forecast, and the company expects a performance loss from January to December 2023, and the net profit attributable to shareholders of listed companies will be -14 billion - 10 billion, net profit decreased by 118 year-on-year41% to 11315%。The company made the above ** based on the following reasons: during the reporting period, affected by changes in market demand, the sales revenue of the company's independent molecular diagnostic reagent products and instruments and equipment declined sharply, and at the same time, the company made provisions for the decline in the price of relevant inventories in accordance with the relevant provisions of the accounting standards for business enterprises and the company's accounting policies, based on the principle of prudence, and the above factors led to a year-on-year decline in operating income and net profit. Shengxiang BiologyOn January 23, Shengxiang Biotechnology released an annual performance forecast, and the company expects a significant decline in performance from January to December 2023, and the net profit attributable to shareholders of listed companies will be 35.6 billion - 38.1 billion, net profit decreased by 82 percent year-on-year00% to 8000%, and the estimated operating income is 100 billion to 102 billion yuan. The company made the above ** based on the following reasons: During the reporting period, the company's operating income and net profit declined, mainly due to the changes in domestic and foreign public health prevention and control policies, resulting in a sharp decline in demand for new crown nucleic acid detection reagents and instruments, and a decline in related business income. The company adjusted and optimized its strategy in a timely manner according to the external environment and market changes, and gradually entered a period of development in its strategic layout in multiple tracks and fields, with endogenous drive and extension growth going hand in hand, showing strong growth potential. The company achieved operating income of 632.54 million yuan in the first three quarters of 2023, and is expected to achieve operating income of 367.46 million yuan to 387.46 million yuan in the fourth quarter of 2023, an increase of 79% to 89% from the previous quarter. In 2023, the company made further breakthroughs in many fields such as respiratory, HPV, blood screening, and sequencing, achieving several times growth compared with the same period of the previous year, and the early layout achieved remarkable results.
Shuoshi BiotechOn January 26, Shuoshi Biotech disclosed the performance pre-loss announcement, and the company expects to achieve a net profit of -3 in 2023500 million to -4300 million yuan, a decrease of 21 compared with the same period last year7.8 billion to 225.8 billion yuan, a year-on-year decrease of 119% to 124%; Non-net profit was -4$1.8 billion to -49.8 billion yuan, a decrease of 21 compared with the same period last year8.4 billion to 226.4 billion yuan, a year-on-year decrease of 124% to 128%.
Oriental Creatures1. According to the preliminary calculation of the financial department, it is expected to achieve a net profit attributable to the owners of the parent company in 2023800 million yuan, there will be a loss; At the same time, the net profit attributable to owners of the parent company was 206,771430,000 yuan (statutory disclosure), an estimated decrease of 244,771430,000 yuan, down 118 year-on-year38%。2. According to the preliminary calculation of the financial department, it is expected that the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses in 2023 will be -42,40000000000000000000000000000000 At the same time, the net profit attributable to owners of the parent company after deducting non-recurring gains and losses was 208,925$580,000 (statutory disclosures), a decrease of $251,325580,000 yuan, down 120 percent year-on-year29%。Hotscape Creatures
On January 31, Hotgen Biotech released an annual performance forecast, and the company expects a significant decline in performance from January to December 2023, with a net profit attributable to shareholders of listed companies of 24000000-3600000,000, net profit decreased by 97 year-on-year46% to 9619%。During the reporting period, in the face of the complexity and changeability of national macroeconomic policies and industry policies, the company always adhered to the concept of innovation and market-oriented, insisted on strengthening the main business of in vitro diagnostics, and actively expanded new fields and strategic layouts to create a development strategy of the whole industry chain from diagnosis to development. Accelerated the promotion of routine clinical testing products, and achieved rapid growth in routine clinical business compared with the same period last year. However, due to the great victory in the fight against the new crown epidemic at home and abroad in 2023, the new crown antigen detection reagent is no longer an urgently needed material for the fight against the epidemic, and the relevant business scope has returned to the pre-epidemic level. The company's operating income decreased significantly compared to last year, resulting in a significant decrease in net profit attributable to owners of the parent company and net profit attributable to owners of the parent company after deducting non-recurring gains and losses.
Matilda BiotechAccording to the latest performance forecast released by the company, it is expected to achieve a net profit of 5,500 in 20230000000-75000000000 yuan, net profit decreased by 98 year-on-year22%—98.69%。The main reasons for the significant decline in the company's net profit attributable to shareholders of listed companies in 2023 and the net profit loss after deducting non-recurring gains and losses are: (1) the company's operating income declined, resulting in a significant decline in the company's net profit; (2) Difficulties in recovering payments from end customers, increased credit risk, and provision for bad debts for some high-risk customers; (3) After the continuous expansion of production capacity in the past three years, the amount of fixed assets of the company is large, resulting in higher depreciation expenses. Cap Biotech
On January 30, Kaipu Biotech released an annual performance forecast, and the company expects a significant decline in performance from January to December 2023, with a net profit attributable to shareholders of listed companies of 13.8 billion - 18 billion, net profit decreased by 92 percent year-on-year00% to 8957%。The company made the above ** based on the following reasons: 1. During the reporting period, the company's net profit decreased year-on-year, mainly due to the decline in demand for the company's related testing products and services due to changes in industry demand, and the sharp year-on-year decline in related business income. During the reporting period, the company continued to embrace the national industrial policy, focusing on maternal and child health, birth defect prevention and control, early tumor screening and individualized drug testing, continued to promote the business development of molecular diagnostic products and medical testing services, and simultaneously strengthened corporate governance, accelerated the research and development of new products and strengthened talent training, so as to achieve high-quality development of the company. Maccura Bio
On January 26, Maccura Biotech released its annual performance forecast, and the company expects a significant decline in performance from January to December 2023, with a net profit attributable to shareholders of listed companies of 28.3 billion - 35.4 billion, net profit decreased by 60 percent year-on-year00% to 5000%, with an estimated operating income of 270.6 billion to 306.7 billion yuan. The company made the above ** based on the following reasons: In 2023, due to the impact of changes in market demand, the sales revenue of molecular diagnostic products in the company's independent products declined significantly, and the provision for impairment of related inventories increased, resulting in a year-on-year decline in operating income and net profit. During the reporting period, the company continued to implement the strategy of "full product line and whole industrial chain" and continuously promoted the realization of the product strategy of "serialization, systematization, automation and independence", and continuously increased the R&D investment of various platforms, and the R&D investment increased significantly year-on-year during the reporting period. On the basis of the company's independent products have gradually been systematized in biochemical, immune, urine, blood cells, coagulation and other multi-platform products and overall laboratory automation solutions, the company has accelerated the construction of its own product marketing system and continuously optimized the product structure. Kehua BiotechOn January 31, Kehua Biotechnology released an annual performance forecast, and the company expects a pre-loss in performance from January to December 2023, and the net profit attributable to shareholders of listed companies will be -24.5 billion - 17.5 billion, net profit decreased by 125 year-on-year24% to 11803%, and basic earnings per share are expected to be -04764 to -03403 yuan. The company continues to deepen its cooperation with international in vitro diagnostic leading enterprises, adheres to the two-wheel drive development strategy of instruments and reagents, continuously improves R&D and innovation capabilities and industrial transformation capabilities, continuously optimizes product costs, improves product quality, and enhances the company's core competitiveness, so as to enhance the company's ability to resist market risks and develop global markets in the future. Nine strong creaturesOn January 22, Jiuqiang Biotech released an annual performance forecast, and the company expects the performance to increase from January to December 2023, and the net profit attributable to shareholders of listed companies will be 50.6 billion -54.5 billion, net profit increased by 30 percent year-on-year00% to 4000%。The company made the above ** based on the following reasons: in 2023, the normal operation of medical institutions across the country, the company's business will return to normal levels, and its products will cover biochemical immunity, blood coagulation, blood grouping, pathological diagnosis and precision diagnosis, and sales revenue and profits will increase. Nuohui HealthOn January 22, Nuohui Health released its 2023 annual report forecast after the close of the Hong Kong Stock Exchange: according to the median pre-audit financial data, as of December 31, 2023, the group's total annual revenue reached 20100 million yuan, an increase of 164% over 2022, and cash collection exceeded 1.4 billion yuan. The annual gross profit was 18400 million yuan, the first year to achieve after-tax profit. LiedmanOn January 30, Liedman released an annual performance forecast, and the company expects to turn around losses from January to December 2023, with a net profit attributable to shareholders of listed companies of 13000000-1900000,000, net profit increased by 123 year-on-year10% to 13376%。The company made the above ** year based on the following reasons, and the diagnosis and treatment activities of domestic hospitals resumed to be based on routine inspections, and the company's overall operating income decreased year-on-year. During the reporting period, the company carried out various operation and management work in an orderly manner in accordance with the annual plan, actively responded to the centralized procurement of biochemical reagents and industry changes, broadened sales channels, and increased market promotion efforts; Optimize internal operation and management processes, implement measures such as reducing costs and increasing efficiency, and strengthening credit control. It is estimated that the amount of asset impairment provision and credit impairment loss in the current period will decrease compared with the same period last year, and the final amount of impairment provision will be determined after evaluation and audit by a professional appraisal agency and audit institution hired by the company. To sum up, the net profit attributable to shareholders of listed companies in the current period is expected to turn losses into profits.
IVD information is compiled from the earnings forecasts of each company.
Statement: The manuscripts marked in this WeChat are **, only for sharing, and do not represent the position of the platform, if it involves copyright and other issues, please contact us as soon as possible, we will correct it as soon as possible, thank you.